Literature DB >> 1902803

Hemimegalencephaly: diagnosis and treatment.

J Q Trounce1, N Rutter, D H Mellor.   

Abstract

Three boys with hemimegalencephaly are reported. Two suffered neonatal convulsions and the third presented with seizures at seven months. In each case the EEG was grossly abnormal, with spike and wave activity. All three have significant developmental delay and demonstrate other manifestations of the condition: macrocephaly in two, contralateral hemiparesis in one and one boy has ipsilateral facial hemihypertrophy and linear naevus. Hemimegalencephaly can be recognised on cranial ultrasonography, and the seizures may respond to benzodiazepine therapy.

Entities:  

Mesh:

Year:  1991        PMID: 1902803     DOI: 10.1111/j.1469-8749.1991.tb05116.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  5 in total

Review 1.  Hemimegalencephaly: clinical implications and surgical treatment.

Authors:  C Di Rocco; D Battaglia; D Pietrini; M Piastra; L Massimi
Journal:  Childs Nerv Syst       Date:  2006-07-05       Impact factor: 1.475

Review 2.  Epilepsy related to developmental tumors and malformations of cortical development.

Authors:  Eleonora Aronica; Peter B Crino
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

3.  Hemimegalencephaly. Histological, immunohistochemical, ultrastructural and cytofluorimetric study of six patients.

Authors:  C Bosman; R Boldrini; L Dimitri; C Di Rocco; A Corsi
Journal:  Childs Nerv Syst       Date:  1996-12       Impact factor: 1.475

4.  Hemimegalencephaly, hemihypertrophy and vascular lesions.

Authors:  A Cristaldi; F Vigevano; G Antoniazzi; M di Capua; A Andreuzzi; G Morselli; F Iorio; G Fariello; G Trasimeni; G F Gualdi
Journal:  Eur J Pediatr       Date:  1995-02       Impact factor: 3.183

Review 5.  Malformations of cortical development and epilepsy.

Authors:  Richard J Leventer; Renzo Guerrini; William B Dobyns
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.